Table 2. Characteristics of study cohort.
| ADPKD | |
|---|---|
| n = 139 | |
| Age—years | 31±7 |
| Sex—no. (%) | |
| Female | 54 (39) |
| Male | 85 (61) |
| Body mass index—kg per m2 | 24±4 |
| BMI <18.5 | 5 (4) |
| BMI 18.5–25 | 81 (58) |
| BMI >25 | 53 (38) |
| eGFR—ml per min per 1.73m2 | 93±19 |
| CKD stage 1 | 74 (53) |
| CKD stage 2 | 61 (44) |
| CKD stage 3 | 4 (3) |
| TKV—cm3 | 860 (568 to 1191) |
| htTKV—cm3 per m | 455 (317 to 669) |
| Hypertension—no. (%)* | |
| Yes | 82 (78) |
| No | 23 (22) |
| Blood pressure—mmHg | |
| Systolic | 131±16 |
| Diastolic | 83±11 |
| Antihypertensive Medication—no. (%) | |
| ACE / ARB | 50 (36) |
| Calcium antagonist | 14 (10) |
| Diuretics | 16 (12) |
Abbreviations: eGFR—estimated glomerular filtration rate. TKV—total kidney volume, htTKV—height adjusted total kidney volume, ACE—angiontensin converting enzyme, ARB—angiotensin II receptor blocker. Values are means ± standard deviation and numbers (percentage), TKV and htTKV are reported as median (interquartile range)
*total number of observations = 105